

Wednesday, January 16, 2008

COMPANY PRESS RELEASE

Transgenomic, Inc. Forms Scientific Advisory Board

Newly formed Advisory Board to advise on cancer screening methods and mitochondrial DNA-based disease detection

OMAHA, NE, January 16, 2008 – Transgenomic, Inc. (**OTC BB: TBIO.OB**) today announced that it has formed a Scientific Advisory Board to advise the Company on the latest developments and scientific opportunities in cancer detection screening and mitochondrial disease diagnosis. The initial members of the board are to include Christopher Corless M.D., Ph.D. of Oregon Health & Science University, Pasi Janne M.D., Ph.D. of the Dana Farber Cancer Institute, Robert Naviaux M.D., Ph.D. of the University of California at San Diego, Bruce H. Cohen M.D. of the Cleveland Clinic, and Dr. Keshav Singh Ph.D. of the Roswell Park Cancer Institute.

Craig Tuttle, Transgenomic's President and Chief Executive Officer, commented, "The formation of this Scientific Advisory Board strengthens Transgenomic's recent emphasis on biomarker development and intellectual property for our clinical reference and pharmacogenomics labs. Their input and leadership will be instrumental in guiding our future product and service offering development efforts. Drs. Janne and Corless bring tremendous expertise in cancer screening and treatment, particularly in receptor tyrosine kinase involvement in cancer, while Drs. Naviaux, Cohen and Singh join to advise us on the many opportunities that exist around mitochondria DNA-based diagnostics in many disease states including diabetes, Parkinson's and cancer. We expect our collaboration with these distinguished researchers will help us to better evaluate both internal and external opportunities and build on our existing expertise and diagnostic offerings in our growing Molecular Diagnostics and Pharmacogenomics Laboratories."

About Transgenomic:

Transgenomic is a global biotechnology company that provides unique products and services for automated high sensitivity genetic variation and mutation analysis. Their offerings include systems, products, discovery and laboratory testing services to the academic and medical research, clinical laboratory and pharmaceutical markets in the fields of pharmacogenomics and personalized medicine. Specific offerings include WAVE[®] DHPLC Systems, related consumables and assay kits, cytogenetics automated systems, Transgenomic Molecular Clinical Reference Laboratory and Pharmacogenomics Research Services. Transgenomic's two laboratory services divisions utilize these technologies and expertise to provide a menu of mutation scanning tests for over 700 cancer-associated genes and more than 60 validated diagnostic tests to meet the needs of pharmaceutical and biotech companies, research and clinical laboratories, physicians and patients. For more information about the innovative systems, products and services offered by Transgenomic, please visit: www.transgenomic.com.

Transgenomic Cautionary Statements

Certain statements in this press release constitute "forward-looking statements" of Transgenomic within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause our actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements include, but are not limited to, those with respect

to management's current views and estimates of future economic circumstances, industry conditions, company performance and financial results, including the ability of the Company to grow its involvement in the diagnostic products and services markets. The known risks, uncertainties and other factors affecting these forward-looking statements are described from time to time in Transgenomic's reports to the Securities and Exchange Commission. Any change in such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred to in such statements. Accordingly, the company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 with respect to all statements contained in this press release. All information in this press release is as of the date of the release and Transgenomic does not undertake any duty to update this information, including any forward-looking statements, unless required by law.

For confirmation of release or further information, please contact:

Debra Schneider
Chief Financial Officer
Transgenomic, Inc.
12325 Emmet Street
Omaha, NE 68164

Phone: 402.452.5400
Fax: 402.452.5461

investorrelations@transgenomic.com